COVID-19 resources / Clinical Research Insights and News

The Cohortias Blog

Stay informed

COVID-19 resources

Cohortias is bringing clinical research to Latin America, now proud to participate in COVID-19 clinical trials.

Our archive includes insights from our experts as they discuss lessons learned over the past three months in managing COVID-19’s impact on trials in Latin America and around the world.

Our blog posts provide insights into what companies should be doing now to prepare for the upcoming ‘new normal’.

trials

Cohortias – What is the Difference Between Phase 3 and 4 Trials?

For a medical treatment to be approved for use by the public, it must go through four phases of clinical trials in order to determine its efficacy and safety.

Pharmacovigilance

Cohortias – Benefits of Outsourcing Pharmacovigilance.

The implementation of an effective pharmacovigilance function is high on the list of priorities for pharmaceutical companies.

clinical

Cohortias – The Basic Components of Clinical Trials.

Each clinical trial has a written plan, or study protocol, that describes the goals of the study, how long the study will last, who can participate.

south america

Conducting Clinical Trials in South America – Cohortias is the Clinical Research Organization.

Cohortias continue to grow in South America. We are a local based Clinical Research Organization with one goal: expand clinical research access across Latin American countries.

COVID-19 Research - Free Consultation

The clinical development journey is fraught with pitfalls and roadblocks; COVID-19 has almost overnight added to the complexity. Innovations, technologies and reinvented processes can help. Our experienced team of experts shares experiences, lessons learned and tips to help you mitigate risk in the current environment while implementing some of the industry’s latest innovations.

covid clinical trials

The presence of clinical research in Latin America has been growing steadily for the last decade, mainly because of cost effectiveness, excellent patient recruitment and the emergence of FDA approved regulatory agencies.